New eczema drug candidate HXN5003 begins first human safety trial
Symptom relief
Not yet recruiting
This early-phase study tests whether a single dose of HXN5003 is safe and tolerable in 28 healthy adults aged 18-55. Researchers will monitor side effects, vital signs, and how the drug moves through the body. This is a first step toward developing a treatment for atopic dermatit…
Phase: PHASE1 • Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd • Aim: Symptom relief
Last updated May 22, 2026 14:03 UTC